Ocugen Faces Mounting Financial Pressure as Losses Deepen

Quarterly Results Highlight Cash Burn Concerns

Gene therapy specialist Ocugen delivered a brutal shock to investors this week, with its shares plummeting amid growing concerns about the company’s financial stability. What initially appeared as a promising pipeline of blindness treatments is increasingly revealing fundamental funding challenges that threaten the company’s future operations.

The company’s latest financial disclosures paint a troubling picture of its fiscal health. Ocugen reported a substantial net loss of $14.7 million last quarter, with operational cash flow showing a deficit of $10 million. Administrative expenses alone accounted for over $6 million in costs during the period.